PPT1 and infantile neuronal ceroid lipofuscinosis: Several ongoing preclinical studies demonstrating the efficacy of Ppt1 enzyme replacement therapy [215–217] as well gene therapy [218, 219] continue to pave the way for clinical trials in INCL patients.